Pharming Group N.V. (PHAR)
PHAR Stock Price Chart
Explore Pharming Group N.V. interactive price chart. Choose custom timeframes to analyze PHAR price movements and trends.
PHAR Company Profile
Discover essential business fundamentals and corporate details for Pharming Group N.V. (PHAR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Dec 2020
Employees
404.00
Website
https://www.pharming.comCEO
Fabrice Chouraqui
Description
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Financial Timeline
Browse a chronological timeline of Pharming Group N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.06, while revenue estimate is $101.28m.
Earnings released on 7 May 2026
EPS came in at -$0.07 falling short of the estimated $0.05 by -240.00%, while revenue for the quarter reached $72.45m , missing expectations by -21.30%.
Earnings released on 12 Mar 2026
EPS came in at $0.07 falling short of the estimated $0.15 by -53.33%, while revenue for the quarter reached $106.50m , missing expectations by -4.71%.
Earnings released on 6 Nov 2025
EPS came in at $0.10 surpassing the estimated $0.05 by +100.00%, while revenue for the quarter reached $97.30m , missing expectations by -0.94%.
Earnings released on 31 Jul 2025
EPS came in at $0.06 surpassing the estimated -$0.10 by +160.00%, while revenue for the quarter reached $93.20m , beating expectations by +12.79%.
Earnings released on 8 May 2025
EPS came in at -$0.22 falling short of the estimated -$0.03 by -780.00%, while revenue for the quarter reached $79.09m , beating expectations by +16.77%.
Earnings released on 13 Mar 2025
EPS came in at $0.05 surpassing the estimated $0.02 by +163.16%, while revenue for the quarter reached $92.70m , beating expectations by +14.09%.
Earnings released on 24 Oct 2024
EPS came in at -$0.02 falling short of the estimated $0.01 by -300.00%, while revenue for the quarter reached $74.85m , missing expectations by -2.71%.
Earnings released on 1 Aug 2024
EPS came in at -$0.01 falling short of the estimated -$0.00 by -400.00%, while revenue for the quarter reached $74.10m , beating expectations by +3.01%.
Earnings released on 8 May 2024
EPS came in at -$0.19 falling short of the estimated $0.01 by -2.00k%, while revenue for the quarter reached $55.60m , missing expectations by -18.74%.
Earnings released on 14 Mar 2024
EPS came in at -$0.03 falling short of the estimated $0.05 by -160.00%, while revenue for the quarter reached $81.20m , beating expectations by +13.05%.
Earnings released on 26 Oct 2023
EPS came in at $0.05 falling short of the estimated $0.13 by -61.54%, while revenue for the quarter reached $66.70m , beating expectations by +8.16%.
Earnings released on 3 Aug 2023
EPS came in at $0.02 surpassing the estimated -$0.02 by +200.00%, while revenue for the quarter reached $54.90m , beating expectations by +3.14%.
Earnings released on 11 May 2023
EPS came in at -$0.17 falling short of the estimated -$0.01 by -1.60k%, while revenue for the quarter reached $42.50m , missing expectations by -15.58%.
Earnings released on 16 Mar 2023
EPS came in at -$0.19 falling short of the estimated $0.01 by -2.00k%, while revenue for the quarter reached $54.62m , missing expectations by -9.35%.
Earnings released on 27 Oct 2022
EPS came in at $0.13 surpassing the estimated $0.03 by +420.00%, while revenue for the quarter reached $151.00m , beating expectations by +182.24%.
Earnings released on 4 Aug 2022
EPS came in at $0.18 surpassing the estimated $0.01 by +1.74k%, while revenue for the quarter reached $50.17m , missing expectations by -3.49%.
Earnings released on 12 May 2022
EPS came in at $0.05 surpassing the estimated -$0.06 by +183.33%, while revenue for the quarter reached $46.62m , missing expectations by -2.17%.
Earnings released on 17 Mar 2022
EPS came in at $0.01 matching the estimated $0.01, while revenue for the quarter reached $52.77m , missing expectations by -8.36%.
Earnings released on 5 Aug 2021
EPS came in at $0.07 surpassing the estimated $0.01 by +620.00%, while revenue for the quarter reached $50.52m , missing expectations by -65.99%.
PHAR Stock Performance
Access detailed PHAR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
